Natco seeks CDSCO approval for phase-III trial of Molnupiravir for COVID-19 treatment

Drug major Natco Pharma on Monday said it has sought approval from the Central Drugs Standard Control Organization (CDSCO) in India for phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients. CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations.
Read more...

;